Planet MicroCap caught up with Cameron Reynolds, President and CEO of VolitionRx Limited (NYSE AMERICAN: VNRX) via Zoom to discuss (Click the time stamp to jump to each answer, or watch it all):

• 0:26 – Volition Announces Expansion of Availability of the Nu.Q® Vet Cancer Test Through IDEXX’s Reference Laboratory Network – what this news and the Heska deal mean for the company?
• 2:30 – What makes Nu.Q test unique and why IDEXX and Heska partnered with them to sell the test through their global networks
• 5:36 – How IDEXX deal came together
• 7:25 – What’s next for VolitionRx?

For more information about VolitionRx Limited, please visit: https://volition.com/

The interview may contain forward looking statements about VolitionRx Limited See VolitionRx Limited’s periodic filings with the Securities and Exchange Commission for more complete information.

About Volition

Volition is a multi-national epigenetics company that applies its Nucleosomics™ platform through its subsidiaries to develop simple, easy to use, cost effective blood tests to help diagnose and monitor a range of life-altering diseases, in both humans and other animals, including some cancers and diseases associated with NETosis such as sepsis and COVID-19. Early diagnosis and monitoring have the potential not only to prolong the life of patients but also to improve their quality of life. The tests are based on the science of Nucleosomics™, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid – an indication that disease is present. Volition’s research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and additional offices in London and Singapore. The contents found at Volition’s website address are not incorporated by reference into this document and should not be considered part of this document. This website address is included in this document as an inactive textual reference only.